AMGEN presents ‘encouraging’ AMG 133 weight loss results
Amgen revealed new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist...
AMGEN presents ‘encouraging’ AMG 133 weight loss results
ICER finds semaglutide more effective, but more expensive
Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesity